Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced a definitive agreement for the purchase and sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share in a registered direct offering. The offering is expected to generate approximately $4.4 million in gross proceeds. Additionally, the company announced a concurrent private placement of unregistered warrants and plans to create an independent business entity composed of its AI platform, withZeta.ai, and related technologies and personnel.
The capital raise and strategic restructuring underscore Lantern's commitment to advancing its precision oncology pipeline while unlocking value from its proprietary AI platform. Proceeds from the offering are intended to support the company's clinical programs, including LP-184, LP-284, and LP-300, as well as the spin-off of withZeta.ai into a standalone entity. This move could allow the AI platform to operate independently, potentially attracting partnerships or investments focused on its broader application in drug development.
Lantern's AI platform, withZeta.ai, is a multi-agentic AI co-scientist platform that is already commercially available as a subscription-based research platform for the global biomedical and drug development community. By spinning off this asset, Lantern aims to create a separate revenue stream and position the platform for growth outside of its own pipeline. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The offering comes at a time when AI-driven drug discovery is gaining traction, with investors increasingly interested in companies that leverage machine learning to reduce the time and cost of developing new therapies. Lantern's RADR platform has been central to its strategy, enabling the identification of biomarker-driven patient populations and optimizing clinical trial designs. The spin-off of withZeta.ai could provide greater flexibility for the platform to serve a wider range of clients, including other biotech and pharmaceutical companies.
Lantern's clinical pipeline includes LP-184, an acylfulvene compound being developed for solid tumors; LP-284, a TC-NER targeting compound for hematologic and solid tumors; and LP-300, a cisplatin/ethacraplatin analog being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.
The company's decision to create an independent entity for its AI platform reflects a broader trend in the biotech industry, where companies are increasingly exploring ways to monetize their technology assets. By separating the AI business, Lantern can potentially unlock shareholder value and attract strategic partners who may be interested in the platform's capabilities without the risks associated with drug development.
Investors and industry observers will be watching closely to see how the spin-off unfolds and whether it leads to new collaborations or licensing deals. The success of this strategy will depend on the platform's ability to demonstrate value in accelerating drug discovery and development for external partners. For more details on the offering, visit the full press release. Additional information about Lantern Pharma is available in the company's newsroom at https://ibn.fm/LTRN.
